Design Therapeutics (DSGN) EBIT (2020 - 2026)

Design Therapeutics has disclosed EBIT across 7 years of filings, most recently posting -$19.7 million for Q1 2026.

• EBIT for Q1 2026 came in at -$19.7 million, up 3.49% year-over-year; the trailing twelve-month figure through Mar 2026 was -$78.8 million (down 15.14% YoY), and the FY2025 annual result was -$79.5 million, down 27.39% from the prior year.
• EBIT came in at -$19.7 million for Q1 2026 at Design Therapeutics, down from -$18.2 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$13.4 million in Q1 2022 to a low of -$22.6 million in Q2 2023.
• The 5-year median for EBIT is -$18.8 million (2023), against an average of -$18.1 million.
• Across the five-year window, EBIT sank 135.39% in 2022 and jumped 33.49% in 2024, its largest moves.
• Design Therapeutics' EBIT stood at -$19.4 million in 2022, then climbed by 22.02% to -$15.1 million in 2023, then fell by 10.4% to -$16.7 million in 2024, then declined by 8.84% to -$18.2 million in 2025, then declined by 8.46% to -$19.7 million in 2026.
• The last three EBIT figures came in at -$19.7 million (Q1 2026), -$18.2 million (Q4 2025), and -$19.3 million (Q3 2025), per Business Quant data.